Diplomat Announces Executive Promotion for Paul Urick
FLINT, Mich. – Feb. 12, 2016 – The nation’s largest independent specialty pharmacy has promoted executive Paul N. Urick, RPh, to Senior Vice President.
Diplomat Pharmacy, Inc. (NYSE: DPLO) is pleased to announce the promotion of Paul Urick to Senior Vice President of Industry Relations, Pharmaceutical Account Management and Payor Strategies effective Jan. 23, 2016.
To learn more about our Diplomat executive team, click here.
In his redefined role at Diplomat, Urick will continue to lead all aspects of Industry Relations and Pharmaceutical Account Management and will now champion efforts in Payor Strategies through the development of specialty initiatives to reduce costs through patient-centered care.
“We are extremely excited to announce the extension of Paul’s role,” said Gary Kadlec, Diplomat president. “Paul brings over 20 years of pharmacy business expertise to Diplomat. In this role, Paul is committed to our pharmaceutical manufacturer and payor partners in meeting their critical needs with cost-saving strategies, adherence-improving technologies and reporting tools that streamline communication.”
Previously, Urick was president of managed markets and industry relations for Burman’s Specialty Pharmacy in Media, Pennsylvania. Before joining Burman’s, Urick served as senior vice president of pharmacy for Cigna Corporation, a Fortune 500 health care company serving over 12 million customers nationally.
Urick also held the position of senior vice president of Pharmacy Services at Independence Blue Cross where he also served as president for FutureScripts and FutureScripts Secure LLC, two pharmacy benefit management companies he created there. Urick also spent 10 years at Geisinger Health System, a nationally leading integrated health system, where he designed and implemented a strategy to transform and insource drug business to form internal PBM operations for Geisinger Health Plan.
Urick continues to serve as an active member of the Academy of Managed Care Pharmacy, the National Association of Specialty Pharmacy and other national associations.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements give current expectations or forecasts of future events or our future financial or operating performance. The forward-looking statements contained in this press release are based on management’s good-faith belief and reasonable judgment based on current information. These statements are qualified by important risks and uncertainties, many of which are beyond our control, that could cause our actual results to differ materially from those forecasted or indicated by such forward-looking statements. For a discussion of such risks and uncertainties, you should review Diplomat’s filings with the Securities and Exchange Commission, including “Risk Factors” in Diplomat’s Annual Report on Form 10-K for the year ended December 31, 2014 and in subsequent reports filed with or furnished to the Securities and Exchange Commission. Except as may be required by any applicable laws, Diplomat assumes no obligation to publicly update such forward-looking statements, which are made as of the date hereof or the earlier date specified herein, whether as a result of new information, future developments or otherwise.
Diplomat (NYSE: DPLO) serves patients and physicians in all 50 states. Headquartered in Flint, Michigan, the company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat opened its doors in 1975 as a neighborhood pharmacy with one essential tenet: “Take good care of patients, and the rest falls into place.” Today, that tradition continues—always focused on improving patient care and clinical adherence. For more information visit www.diplomat.is. Follow us on Twitter and LinkedIn and like us on Facebook.
Kali Lucas, Public Relations Coordinator
810.768.9580 | email@example.com
@DiplomatRx@JNJNews treatment Zytiga significantly cut the death risk for ... prostate cancer patients by 38% https://t.co/6Ga1okf4Ye @ASCO #ASCO174 days ago
@sloan_ketteringRT @sloan_kettering: Your immune system provides one of the best defenses against cancer. But sometimes it needs a little help. More about…2 weeks ago
@DiplomatRxThank you to @corpmagazine for recognizing Diplomat as a 2017 Michigan Economic Bright Spot awardee!2 weeks ago
@DiplomatRxFriend and Patient Advocate, Brenda Williams Hawkes was featured in @MyGoodDays Days this month!… https://t.co/TFGSoMecqO2 weeks ago
@DiplomatRxJeff Park Elected to Diplomat Board of Directors https://t.co/IMI1aRwNbm3 weeks ago